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Corticosteroids manifest to have anti-inflammatory and immunosuppressive actions and have been used to treat various diseases for more than 50 years. Although it is known that long-term application of corticosteroids can cause various side effects in the body, it is still uncertain whether they are ulcerogenic to the gastrointestinal tract. Clinical studies showed inconsistent results regarding the association of corticosteroid usage and peptic ulcer formation (Conn and Blitzer, 1976; Messer et al., 1983) . Administration of corticosteroids to experimental animals resulted in acute gastric erosions (Nobuhara et al., 1985; Wallace, 1987; Filep et al., 1992) , but other studies showed that dexamethasone, a potent corticosteroid, did not induce gastric lesions (Akiba et al., 1998; Gretzer et al., 2001 ).
In fact, peptic ulcer formation is a dynamic state of imbalance between aggressive and protective factors. It has been suggested that the mechanisms responsible for gastric mucosal damage induced by corticosteroids include inhibition of gastric mucus synthesis, enhancement of gastrin and parietal cell hyperplasia with augmented acid secretion, and suppression of arachidonic acid metabolism and prostaglandin (PG) synthesis (Menguy and Masters, 1963; Delaney et al., 1979; Bandyopadhyay et al., 1999; Wolfe et al., 1999) .
The mechanism for ulcer repair represents a different entity of process including the balance of cell damage and repair at the ulcer site. Corticosteroids given in ulcerogenic doses could not only damage the mucosa but also affect the regenerative system in the gastric mucosa, both of which could delay ulcer healing in the stomach (Carpani de Kaski et al., 1995) , This article has not been copyedited and formatted. The final version may differ from this version. It is difficult to differentiate the two actions on ulcer repair. There is no detailed mechanistic study reporting the direct action of corticosteroids on ulcer healing in the stomach. Thus, it is interesting to investigate whether a non-ulcerogenic dose of corticosteroid could indeed affect cell proliferation, angiogenesis and apoptosis at the ulcer site during ulcer healing. All these parameters have been shown to be important in tissue repair in the stomach (Carpani de Kaski et al., 1995; Li et al., 1999; Wang et al., 2000) .
Corticosteroids can affect PG synthesis in tissues (Flower, 1988; Izhar et al., 1992) and PGs play a significant role in the prevention of ulcer formation and improvement of ulcer healing (Cho et al., 1990; Kuwayama et al., 1991; Carpani de Kaski et al., 1995) . It is therefore suggested that depletion of PGs could be the major detrimental factor contributing to the action of corticosteroids on ulcer repair in the stomach. In this regard, enzymes involved in PG synthesis including phospholipase A 2 (PLA 2 ) which influences the production of arachidonic acid and cyclooxygenases (COXs) which contribute to the formation of different forms of PG, play a significant role in the action of corticosteroids on ulcer healing.
In this study, we would like to apply the non-ulcerogenic doses of dexamethasone, a potent corticosteroid, to explore its action on ulcer healing and the mechanistic pathway related to PG synthesis in a rat gastric ulcer model. This article has not been copyedited and formatted. The final version may differ from this version. 
Methods
Animals.
The use of animals in this study was approved by the Committee on the Use of Live Animals in Teaching and Research of The University of Hong Kong. Male Sprague-Dawley rats (200-220g) were reared on a standard laboratory diet and given tap water. They were kept in a room where temperature (22 ± 1 o C), humidity (65 -70%), and day/night cycle (12h: 12h light/dark) were controlled. Rats were fasted for 24 hours but had free access to water before being subjected to acetic acid to produce gastric ulcer.
Chemicals and drugs.
Chemicals and drugs were purchased from Sigma Chemical Co. unless otherwise stated.
Dexamethasone was prepared in 1% ethanol vehicle for intragastric administration. PGE 2 was dissolved in 0.01M phosphate buffer saline for intraperitoneal injection.
Part I: Dexamethasone treatment and mucosal damage
To determine the non-ulcerogenic dose of dexamethasone, rats were given dexamethasone intragastrically at the maximal dose of 0.2 mg/kg once daily for a period of 9 days. They were sacrificed on day 10 and the gastric mucosa damage was assessed by morphological observation under magnifying glass and histological examination with a This article has not been copyedited and formatted. The final version may differ from this version. microscope. The specimens with Hematoxylin-Eosin stain were assessed according to the criteria of Whittle and associates (Whittle et al., 1990) with modification. The microscopic scoring was defined as follows: 1) epithelial cell damage and glandular disruption, 2) hemorrhagic damage in the mucosa, 3) deep necrosis and ulceration. For further comparisons in this part with the other portions of the study, we also collected mucosae from normal rats without any treatment as the normal group.
Part II: Dexamethasone treatment and ulcer healing
Induction of gastric ulcer.
Gastric kissing ulcers were produced by luminal application of acetic acid solution to rats as previously described with modification (Tsukimi and Okabe, 1994) . Briefly, the abdomen was opened under ether anesthesia and the stomach was exposed. The anterior and posterior walls of the stomach were clamped together with a pair of forceps with a round ring (i.d. 10mm) situated between the two arms of the forceps. A 60% acetic acid solution of 0.12 ml was injected into the clamped portion through the forestomach via a 21-gauge needle. After forty-five seconds, the acid solution was removed and the abdomen was closed. Thereafter, rats were fed a standard diet and given tap water.
This article has not been copyedited and formatted. The final version may differ from this version. One day after ulcer induction, rats were given dexamethasone intragastrically at doses of 0.1 or 0.2 mg/kg once daily for 3, 6, or 9 days to observe the ulcer-healing effect. Rats receiving 1% ethanol solution were regarded as vehicle control. There were no observable differences in the daily physical activities and body weight gain between the control and the dexamethasone-treated groups during the experimental period. After treatment, rats were sacrificed at day 4, 7, or 10 after ulcer induction. The ulcer size (mm 2 ) on both the anterior and posterior walls were determined in each stomach. After measuring the ulcer areas, gastric tissues were excised for immunohistological analysis. Gastric mucosa and submucosa over the ulcer margins were removed by scraping with a glass slide and immediately frozen in liquid nitrogen and stored at -70 o C until determinations for different parameters.
Assessment of mucosal mucus content.
After fixation in buffered formalin and immersion in wax, 5-µm sections were made and stained with periodic acid-Schiff (PAS) technique. Finally, they were counterstained with from both sides of ulcer margins and expressed as the ratio of the thickness of the mucus layer to the thickness of the total mucosa .
Assessment of epithelial proliferation at ulcer margin.
To determine cell proliferation, a single dose of 100 mg/kg 5-bromo-2'-deoxyuridine (BrdU) was injected intraperitoneally one hour before animals were sacrificed. The cell proliferation was assessed by immunohistochemical staining with anti-BrdU antibody as described previously (Lacy et al., 1991) . The sections were counterstained with Mayer's hematoxylin. The cells labeled with BrdU at a field of 0.899 mm 2 (200X) was counted in both sides of ulcer margin of the ulcer crater for each rat and expressed by taking the average of both sides of the ulcer margin.
Determination of angiogenesis at ulcer margin and base.
The microvessels at the ulcer margin and base in the granulation tissue of the submucosa was identified by immunohistochemical staining with von Willebrand factor antibody (DAKO, Glostrup, Denmark) (Augustin et al., 1995) The microvessels stained with the antibody were quantified at the two sides of the ulcer margin and at the base of ulcer crater in a microscopic field of 0. Terminal deoxy-transferase (TdT)-mediated dUTP-biotin nick end labeling (TUNEL) method was used to stain apoptotic cells, as described previously (Gavrieli et al., 1992) . The number of apoptotic cells was counted under in a microscopic field of 0.899mm 2 (200X) and was expressed by taking the average of both sides of ulcer margin.
Western blotting for COX-1, COX-2, and cPLA 2 expressions.
Gastric tissues were homogenized (Ultra-Turrax, Janke & Kunkel Co, Staufen, Germany)
with RIPA buffer (50mM Tris-HCl, pH 7.5, 150mM NaCl, 0.1% SDS, 0.5% α-cholate, 2mM
EDTA, 1% Triton-X, 10% glycerol) and then centrifuged (J2-21, Beckman Instrument, CA) for supernatants. Protein concentration was measured using a protein assay kit with BSA as a standard (Bio-Rad Laboratories, Hercules, CA). Proteins were separated by electrophoresis on a 7.5% (COX-1, COX-2) or 5% (cPLA 2 ) SDS-acrylamide gel, and then transferred to Hybond 
Measurement of mucosal PGE 2 level.
Gastric tissues were homogenized with homogenizing buffer (0.05M Tris-HCL at pH7.4, 0.1M NaCl, 0.001M CaCl 2 , 1mg/mL D-glucose, 28µM indomethacin to inhibit further PGE 2 formation) for 30 seconds. They were then centrifuged at 12000 rpm for 15 minutes at 4 o C.
Supernatants were assayed by using a commercial available PGE 2 ELISA kit (Quantikine, R&D systems Inc, Minneapolis, MN). The assay procedure was in accordance to the protocol suggested by the manufacturer. Optical densities were determined by the MRX microplate reader (Dynex Technologies, Chantilly, VA) at 405 nm. The amount of protein in the sample was determined by a protein assay kit and the mucosal PGE 2 level was expressed as pg/mg protein.
Part III: PGE 2 and dexamethasone treatments on ulcer healing
One day after ulcer induction, rats were given PGE 2 (intraperitoneal injection at 100 or 
Statistical analysis.
The results were expressed as means ± S.E.M. The number of animals in each group used was ranging from eight to ten. Differences between means were analyzed with Student's t-test
and one-way analysis of variance (ANOVA) when appropriate. P values of <0.05 were considered statistically significant. In order to avoid subjective bias on the assessment of histological parameters measured in this study, samples were blinded from the observers when they were determined.
This article has not been copyedited and formatted. The final version may differ from this version. 
Results
Effect of dexamethasone on gastric mucosal damage.
There were no observable petechiae or erosions found in the gastric glandular mucosa after 9 days of 0.2 mg/kg dexamethasone treatment. Microscopically, the epithelium of mucosa and glandular architecture were intact and there was no sign of hemorrhage or inflammatory cells in the mucosal and submucosal layers of the stomach.
Effect of dexamethasone on gastric ulcer healing.
The average ulcer sizes in the control were similar to those of the dexamethasone treatment groups in day 4 after ulcer induction. On day 7 and day 10, ulcer sizes were dose-dependently increased in the dexamethasone-treated groups. Significant effect was indicated in the higher dose of dexamethasone when compared with the control group in day 7 and also in day 10 after ulcer induction, implicating that dexamethasone could delay ulcer healing (Fig. 1) .
Effect of dexamethasone on thickness of gastric mucus layer.
The thickness of mucus layer at the ulcer margin was the highest and significantly decreased from there to the adjacent normal mucosa. The thickness of mucus layer in the gastric mucosa was higher in day 4 than in day 7 after ulcer induction. Dexamethasone treatment dose-dependently decreased the thickness of mucus layer at all parts of the mucosa, especially at the ulcer margin in day 4 and day 7 after ulcer induction when compared to those of the control group (Table 1) .
Effect of dexamethasone on epithelial cell proliferation at the ulcer margin.
Epithelial cell proliferation in the control group was increased significantly at the ulcer margin after ulcer induction when compared to those of normal mucosa (p < 0.01).
Dexamethasone treatment dose-dependently decreased epithelial cell proliferation at the ulcer margin in day 4 and day 7 after ulcer induction when compared to those of the respective control group (Fig. 2) .
Effect of dexamethasone on angiogenesis at the ulcer margin and base.
Again, the number of blood vessels at the ulcer margin and base was markedly increased 4 and 7 days after ulcer induction (p < 0.01). Administration dexamethasone significantly decreased numbers of microvessels at ulcer base and ulcer margin in day 4 and day 7 after ulcer induction in a dose-related manner when compared to those of the respective control group (Fig. 3) .
This article has not been copyedited and formatted. The final version may differ from this version. Effect of dexamethasone on apoptosis at the ulcer margin.
The number of apoptotic cells in the epithelium was significantly increased at the ulcer margin only on day 7 after ulcer induction when compared to that of the normal mucosa (p < 0.05). Dexamethasone did not significantly affect the number of apoptotic cells in the gastric epithelium at the ulcer margin 4 and 7 days after ulcer induction ( Table 2) .
Effects of dexamethasone on protein expressions of COX-1, COX-2, and cPLA 2 at the ulcer margin.
COX-2 protein expression was very weak in intact normal gastric mucosa. Ulcer induction markedly increased the COX-2 protein expression by more than five folds when compared to the normal mucosa (p < 0.001). Dexamethasone dose-dependently decreased COX-2 protein expression at the ulcer margin at day 4 and day 7 after ulcer induction when compared to the respective control group (Fig. 4a) . Again significant effect was observed at the higher dose of dexamethasone. However, COX-1 protein expression in the gastric mucosa was not significantly different among the normal group, control group, and the dexamethasone-treated groups (Fig. 4b) .
Regarding the cPLA 2 protein expression, ulcer induction did not significantly alter the expression of this protein in the gastric mucosa, although dexamethasone had a tendency to reduce the protein level in day 4 and day 7 after ulcer induction (Fig. 4c ).
This article has not been copyedited and formatted. The final version may differ from this version. level at the ulcer margin in day 4 and day 7 after ulcer induction when compared to those of the respective control group (Fig. 5) .
Reversal of PGE 2 treatment on the effects of dexamethasone on ulcer healing.
PGE 2 administration at the doses of 100 or 200 µg/kg dose-dependently reversed the adverse action of dexamethasone on the delay of ulcer healing at day 7 after ulcer induction (Fig. 6) . The same doses of PGE 2 also significantly attenuated the inhibitory actions of dexamethasone on the number of proliferative cells at the ulcer margin (Fig. 7) and also the number of blood vessels at the ulcer margin and base (Fig. 8 ).
Discussion
In the current study, we demonstrated for the first time that dexamethasone given at non-ulcerogenic doses 0.1 or 0.2 mg/kg/day relevant to those used in different clinical conditions ranging from 0.05 -0.2 mg/kg/day or its equivalent dose (Vecht 1998; Chatham and Kimberly 2001; Singh et al., 2002; Yang and Lichtenstein 2002) , delayed gastric ulcer healing.
To further explore this problem, we used the gastric ulcer model to investigate the pathological mechanism of dexamethasone on ulcer healing.
In this study, the highest dose of dexamethasone 0.2 mg/kg/day for 9 days did not affect the basal mucosal PGE 2 level, in which the expression of COX-2 was extremely low and the COX-1 expression was unaffected (Fig.4) . These results demonstrated that dexamethasone at this dosage, did not inhibit COX-1 protein expression and its biological activity. This finding also coincided with our finding that dexamethasone under this dosage did not induce mucosal damage because inhibition of both COX-1 and COX-2 were essential for gastric injury in animals (Wallace et al., 2000) . However, previous studies showed discordant results regarding glucocorticoid-associated mucosa damage (Nobuhara et al., 1985; Wallace, 1987; Filep et al., 1992; Akiba et al., 1998; Gretzer et al., 2001 ). These dichotomy findings may be due to different dosages and administration frequency of corticosteroid at different time intervals in evaluating mucosal injury. Our approaches in the selection of dosages and the duration of drug treatment were more relevant to those in clinical situations. Therefore, the current findings with dexamethasone on ulcer healing could have significant implications in gastric ulcer patients.
Our study also showed that COX-2 protein expression and PGE 2 formation were significantly increased at the ulcer margin at day 4 and day 7 after ulcer induction when compared to those of the normal group, but the protein expression of COX-1 and cPLA 2 were unaffected. These findings implicated that the increase of PGE 2 in the gastric mucosa after ulcer induction was largely derived from the activation of COX-2. Furthermore, dexamethasone dose-dependently decreased COX-2 expression and PGE 2 formation without affecting COX-1 and cPLA 2 expressions, confirmed further the above phenomenon. These results were consistent with previous reports stating that COX-1 was constitutive and COX-2 was inducible by cytokines and growth factors during ulceration. Dexamethasone only decreased COX-2 expression and the PGE 2 formation by this enzyme (Wolfe et al., 1999; Fernandez-Morata et al., 2000; Gretzer et al., 2001) . Previous studies showed that glucocorticoid inhibited PLA 2 activity which influenced the liberation of arachidonic acid, a precursor for PG synthesis (Flower, 1988; Goppelt-Struebe et al., 1989) . Our result revealed that ulcer induction did not affect the expression of cPLA 2 , suggesting that the amount of arachidonic acid in the gastric mucosa could be sufficient enough to support the elevated COX-2 activity due to ulceration to produce more PGE 2 in the tissue. It is therefore suggesting that cPLA 2 is not the limiting enzyme for PGE 2 synthesis during ulceration in the gastric Ulcer induction initiated epithelial cell proliferation and angiogenesis at the ulcer margin.
Both of them play a pivotal role in ulcer healing Wang 2002) . At the non-ulcerogenic doses of dexamethasone, it significantly inhibited cell proliferation and angiogenesis at the ulcer margin. As discussed before, dexamethasone decreased COX-2 expression and PGE 2 formation at the same site, both of them are important factors for gastric ulcer healing (Mizuno et al., 1997) . COX-2 derived PGE 2 increases vascular endothelial growth factor expression, which stimulates endothelial cell proliferation and angiogenesis (Ghosh et al., 2000; Szabo et al., 2000; Pai et al., 2001 ). This may be the reason why dexamethasone decreased angiogenesis at the ulcer margin and ulcer base. PG also can induce the expression of hepatocyte growth factor, which strongly stimulates proliferation of gastric epithelial cells (Takahashi et al., 1996) . In addition, PGE 2 rapidly phosphorylates epidermal growth factor receptor and triggers the extracellular signal-regulated kinase 2-mitogenic signaling pathway in normal gastric epithelial cell lines . All these could lead to more cell proliferation at the ulcer margin. This might explain why depletion of PGE 2 by dexamethasone could decrease epithelial cell proliferation as well as angiogenesis at the ulcer margin and thereby delay ulcer healing in the stomach, whereas supplementation with PGE 2 dose-dependently resumed these ulcer-healing processes back to normal rate in the gastric mucosa.
This article has not been copyedited and formatted. The final version may differ from this version. In this study, we also found that mucus thickness at the ulcer margin was increased profoundly after ulcer induction. This could be a positive biological feedback mechanism to preserve the ulcer from further ulceration and promote ulcer healing .
Dexamethasone administration markedly decreased gastric mucus thickness and weakened the defensive mechanism in the gastric mucosa. In fact, dexamethasone could down-regulate gastric mucin gene expression and thereby decrease mucin biosynthesis (Okazaki et al., 1998) .
PG deficiency also impairs gastric mucus production (Menguy and Masters, 1963) . It is likely that the reduction of mucus layer induced by dexamethasone could be the result of its direct action on mucin gene expression in the nucleus and also indirectly through the depletion of PG in the gastric mucosa.
In conclusion, ulcer induction activates the repairing system in the gastric mucosa. This system includes mucus secretion, epithelial cell proliferation and angiogenesis at the ulcer margin in order to promote ulcer healing in the stomach. Dexamethasone given at non-ulcerogenic doses could deter such defensive mechanisms at the early stage of the regenerative mechanism. These adverse actions were probably due to the down-regulation of COX-2 and depletion of PGE 2 in the gastric mucosa. The present study reports for the first time that dexamethasone given at non-ulcerogenic doses similar to those in humans, could worsen the ulcer healing process through a defined mechanism in rat stomachs. 
